



**Fujisawa Pharmaceutical Co.,Ltd.  
Corporate Communications**

4-7, Doshomachi 3-chome, Chuo-ku, Osaka 541-8514, Japan  
Telephone : 81-6-6206-7857 Facsimile : 81-6-6206-5016  
URL <http://www.fujisawa.co.jp/>  
E-mail : [corporatec@po.fujisawa.co.jp](mailto:corporatec@po.fujisawa.co.jp)

February 25, 2003

For Further Information  
Yukio Shimonaka, Director  
Corporate Communications

**Fujisawa Submits Application for Marketing Authorization of  
Micafungin , A Candin Antifungal Agent, in Europe**

Japan, February 25, 2003 - Fujisawa Pharmaceutical Co., Ltd., today announced that Fujisawa GmbH, a wholly owned subsidiary of the Company, submitted an application for Marketing Authorization of micafungin, an injectable candin antifungal agent, in Europe on February 17, 2003, in order to seek approval for the treatment of deep-seated fungal infections.

Micafungin is a candin antifungal agent generated by Fujisawa as the first in this class in Japan, and the Company has been simultaneously developing micafungin both in Japan and overseas. Micafungin was launched in Japan as “Fungard® for Infusion” in December 2002 and it is now being recognized as a drug contributing to the treatment of deep-seated fungal infections. In the U.S., Fujisawa Healthcare, Inc. submitted an NDA for micafungin to the FDA in April 2002. On January 29, 2003, Fujisawa Healthcare received communications from the FDA regarding the status of the micafungin NDA review and is now working closely with the FDA to meet their requirements for approval. Micafungin has also been filed in Canada since June 2002

#####